[go: up one dir, main page]

UY28692A1 - Nuevos derivados de quinolina - Google Patents

Nuevos derivados de quinolina

Info

Publication number
UY28692A1
UY28692A1 UY28692A UY28692A UY28692A1 UY 28692 A1 UY28692 A1 UY 28692A1 UY 28692 A UY28692 A UY 28692A UY 28692 A UY28692 A UY 28692A UY 28692 A1 UY28692 A1 UY 28692A1
Authority
UY
Uruguay
Prior art keywords
compounds
quinolina
formula
new derivatives
relates
Prior art date
Application number
UY28692A
Other languages
English (en)
Inventor
Robert Steven Kania
Yufeng Hong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28692(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of UY28692A1 publication Critical patent/UY28692A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a los compuestos representados por la fórmula y a las sales o solvatos farmacéuticamente aceptables de dichos compuestos, en los que cada uno de A R3-8, X3, X5, m, y n son como se han definido en esta memoria descriptiva. La invención también se refiere a las composiciones farmacéuticas que contienen los compuestos de fórmula (I) y a los procedimientos de tratamiento de trastornos hiperproliferativos en un mamífero mediante la administración de compuestos de fórmula (I).
UY28692A 2003-12-23 2004-12-21 Nuevos derivados de quinolina UY28692A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53272503P 2003-12-23 2003-12-23

Publications (1)

Publication Number Publication Date
UY28692A1 true UY28692A1 (es) 2005-07-29

Family

ID=34738830

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28692A UY28692A1 (es) 2003-12-23 2004-12-21 Nuevos derivados de quinolina

Country Status (33)

Country Link
US (2) US7381824B2 (es)
EP (1) EP1699780A1 (es)
JP (1) JP4503022B2 (es)
KR (1) KR100807920B1 (es)
CN (1) CN1890234A (es)
AP (1) AP2006003619A0 (es)
AR (1) AR048292A1 (es)
AU (1) AU2004309166B2 (es)
BR (1) BRPI0418102A (es)
CA (1) CA2551508C (es)
CR (1) CR8482A (es)
EA (1) EA009994B1 (es)
EC (1) ECSP066671A (es)
GE (1) GEP20084572B (es)
GT (1) GT200400274A (es)
HN (1) HN2004000544A (es)
IL (1) IL175947A (es)
IS (1) IS8439A (es)
MA (1) MA28396B1 (es)
MX (1) MXPA06007242A (es)
MY (1) MY139446A (es)
NL (1) NL1027847C2 (es)
NO (1) NO20063382L (es)
NZ (1) NZ547009A (es)
OA (1) OA13349A (es)
PE (1) PE20050757A1 (es)
SG (1) SG141459A1 (es)
TN (1) TNSN06200A1 (es)
TW (1) TWI331148B (es)
UA (1) UA82577C2 (es)
UY (1) UY28692A1 (es)
WO (1) WO2005063739A1 (es)
ZA (1) ZA200603657B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06007242A (es) * 2003-12-23 2006-08-18 Pfizer Nuevos derivados de quinolina.
CA2553433A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
KR20080027923A (ko) * 2005-08-08 2008-03-28 화이자 인코포레이티드 Ｖｅｇｆ-ｒ 억제제의 염 및 다형체
WO2007066181A2 (en) * 2005-12-05 2007-06-14 Pfizer Products Inc. Methods of preparing a vegf-r inhibitor
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8163923B2 (en) * 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
PT2154967E (pt) 2007-04-16 2014-06-05 Hutchison Medipharma Entpr Ltd Derivados de pirimidina
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2340244A4 (en) 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
IT1393351B1 (it) * 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
KR20110133048A (ko) * 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
US9309238B2 (en) 2009-11-05 2016-04-12 University Of Notre Dame Du Lac Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
FR2973703A1 (fr) * 2011-04-08 2012-10-12 Univ Provence Aix Marseille 1 Derives de 4-arylcoumarine et de 4-arylquinoleine, leurs utilisations therapeutiques et leur procede de synthese
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
EP3763710A1 (en) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JP6301374B2 (ja) 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN103524409B (zh) * 2013-09-26 2015-09-02 上海仁力医药科技有限公司 喹啉类化合物及其制备方法与应用
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
CN105213394B (zh) * 2014-06-06 2019-04-09 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
CN104628686A (zh) * 2015-01-27 2015-05-20 南通恒盛精细化工有限公司 一种带酰胺侧链的苯并呋喃制备工艺
CN106046007B (zh) * 2015-04-07 2019-02-05 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
BR112018005208B1 (pt) 2015-09-17 2023-12-12 Marvin J. Miller Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana
KR20180086187A (ko) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
US10766862B2 (en) 2016-09-30 2020-09-08 Guangdong Raynovent Biotech Co., Ltd. Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
CN107337634B (zh) * 2017-08-28 2019-07-09 新发药业有限公司 一种阿贝西利中间体化合物的制备方法
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
KR20210151818A (ko) 2019-04-12 2021-12-14 내셔날 헬스 리서치 인스티튜트 치료 용도를 위한 키나제 억제제로서의 헤테로사이클릭 화합물
WO2023138674A1 (zh) * 2022-01-21 2023-07-27 默达药物（香港）有限公司 N-羟基喹啉甲酰胺化合物及其用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE317376B (es) * 1961-07-10 1969-11-17 Roussel Uclaf
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3936461A (en) * 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
JPS62168137A (ja) * 1985-12-20 1987-07-24 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料およびその処理方法
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1992021660A1 (en) 1991-05-29 1992-12-10 Pfizer, Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5506235A (en) 1991-08-02 1996-04-09 Pfizer Inc. Quinoline derivatives as immunostimulants
GB9127252D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
PL315941A1 (en) 1994-02-23 1996-12-09 Pfizer 4-heterocyclic substituted derivatives of quinazoline, methods of obtaining them and their application as anticarcinogenic agents
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (es) 1994-11-12 1997-12-01 Zeneca Ltd
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DK0831829T3 (da) 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
JP4009681B2 (ja) 1995-11-07 2007-11-21 キリンファーマ株式会社 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
EP0907649A1 (en) * 1996-06-27 1999-04-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
AR007855A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6809097B1 (en) * 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
JP4495257B2 (ja) 1997-02-19 2010-06-30 バーレツクス ラボラトリーズ インコーポレーテツド Ｎｏｓ抑制剤としてのｎ−複素環誘導体
ATE292623T1 (de) 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
WO1998051344A1 (en) 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
WO1998054093A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
UA72881C2 (uk) * 1997-11-11 2005-05-16 Пфайзер Продактс Інк. Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
AU3850299A (en) 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
IL139934A0 (en) 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
UA72749C2 (en) * 1998-09-29 2005-04-15 White Holdings Corp Substituted 3-cyanoquinolines, a method for the preparation thereof (variants), pharmaceutical composition based thereon, a method for the treatment, inhibiting the growth or elimination of neoplasms and a method for the treatment, inhibiting progressing or elimination of polycystic kidney disease using them
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
JP2002533406A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 新生物の治療における併用療法として、金属プロティナーゼ抑制剤および一またはそれ以上の抗新生物剤を用いる方法
ES2281591T3 (es) * 1999-01-22 2007-10-01 Kirin Beer Kabushiki Kaisha Derivados de n-((quinolinil)oxil)-fenil)-urea y de n-((quinazolinil)oxil)-fenil)-urea con actividad antitumoral.
SK288378B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Použitie chinazolínových derivátov ako inhibítorov angiogenézy
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
EP1243582A4 (en) * 1999-12-24 2003-06-04 Kirin Brewery QUINOLINE, QUINAZOLINE DERIVATIVES, AND MEDICINES CONTAINING SUCH SUBSTANCES
CA2395414A1 (en) 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd Condensed purine derivative
EP1265635A1 (en) 2000-03-22 2002-12-18 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
IL151992A0 (en) 2000-03-31 2003-04-10 Imclone Systems Inc Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
WO2001085796A2 (en) 2000-05-12 2001-11-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
CA2415469A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
KR100389127B1 (ko) 2000-10-09 2003-06-25 동부한농화학 주식회사 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
WO2002030453A1 (en) 2000-10-12 2002-04-18 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
RU2264389C3 (ru) * 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
ES2290199T3 (es) 2000-11-22 2008-02-16 Novartis Ag Mezcla que incluye un agente que reduce la actividad de fcve y un agente que reduce la actividad de fce.
WO2002064170A1 (en) 2001-02-09 2002-08-22 Children's Medical Center Corporation A method for treating cancer and increasing hematocrit levels
JP2005515967A (ja) 2001-07-13 2005-06-02 イムクローン　システムズ　インコーポレイティド 乳癌を治療するためのｖｅｇｆｒ−１抗体
US7495104B2 (en) * 2001-10-17 2009-02-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
JP2005506366A (ja) 2001-10-25 2005-03-03 ノバルティス アクチエンゲゼルシャフト 選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤
WO2003074529A2 (en) * 2002-03-01 2003-09-12 Pfizer Inc. iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
US7560558B2 (en) 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
MXPA05001536A (es) 2002-08-30 2005-04-19 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
MXPA06007242A (es) * 2003-12-23 2006-08-18 Pfizer Nuevos derivados de quinolina.

Also Published As

Publication number Publication date
US7381824B2 (en) 2008-06-03
AP2006003619A0 (en) 2006-06-30
JP2007516273A (ja) 2007-06-21
JP4503022B2 (ja) 2010-07-14
US7923457B2 (en) 2011-04-12
MXPA06007242A (es) 2006-08-18
UA82577C2 (en) 2008-04-25
CA2551508A1 (en) 2005-07-14
AU2004309166B2 (en) 2008-02-21
CA2551508C (en) 2011-08-09
SG141459A1 (en) 2008-04-28
PE20050757A1 (es) 2005-10-31
KR100807920B1 (ko) 2008-02-27
GT200400274A (es) 2005-09-20
MA28396B1 (fr) 2007-01-02
AR048292A1 (es) 2006-04-19
MY139446A (en) 2009-10-30
WO2005063739A1 (en) 2005-07-14
US20050137395A1 (en) 2005-06-23
BRPI0418102A (pt) 2007-04-27
CR8482A (es) 2007-12-17
US20090069316A1 (en) 2009-03-12
NO20063382L (no) 2006-09-20
IS8439A (is) 2006-05-04
AU2004309166A1 (en) 2005-07-14
IL175947A (en) 2012-08-30
GEP20084572B (en) 2008-12-25
NZ547009A (en) 2009-09-25
EA009994B1 (ru) 2008-06-30
HN2004000544A (es) 2010-06-09
NL1027847A1 (nl) 2005-06-27
ZA200603657B (en) 2007-08-29
CN1890234A (zh) 2007-01-03
ECSP066671A (es) 2006-10-25
EP1699780A1 (en) 2006-09-13
TWI331148B (en) 2010-10-01
KR20060101548A (ko) 2006-09-25
TNSN06200A1 (fr) 2007-11-15
IL175947A0 (en) 2006-10-05
NL1027847C2 (nl) 2006-04-19
EA200600892A1 (ru) 2006-12-29
TW200526218A (en) 2005-08-16
OA13349A (en) 2007-04-13

Similar Documents

Publication Publication Date Title
UY28692A1 (es) Nuevos derivados de quinolina
CR8744A (es) Compuestos terapeuticos
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
UY28691A1 (es) Derivados de difenilazetidona
NI200900204A (es) COMPUESTOS AMINO-HETEROCÍCLICOS. Caso: PC 33468A
UY28186A1 (es) N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos.
NI200700102A (es) Derivados de indol tetraciclicos como agentes antiviricos
ECSP099319A (es) Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus
UY30334A1 (es) Derivados de triazolopirazina
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP067054A (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
ECSP066717A (es) Compuestos de quinolina sustituidos
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
ECSP078052A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
GT200700096A (es) Compuestos de pirazolina
ECSP078051A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
BRPI0818626A2 (pt) n-fenil-bipirrolidina carboxamidas substituída e uso terapêutico da mesma
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
PA8589801A1 (es) Aminoalcoxiindoles
UY29308A1 (es) Derivado de quinolina, su uso, preparación y medicamento que lo contiene

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120605